Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
$96M
Total Raised
Series C
Latest Round
2019
Founded
90+
Employees
Los Angeles, CA
1 min read
Quick Facts
Valuation
$500M
Latest Round Size
$96M
Latest Round Date
October 2025
Torl Biotherapeutics: Series C Funding Round
Torl Biotherapeutics has successfully raised $96M in Series C funding, reaching a valuation of $500M.
Company Overview
Antibody-based immunotherapies for cancer patients
Funding Details
The Series C round was led by Cormorant Asset Management, with participation from BVF Partners.
Company Information
- Headquarters: Los Angeles, CA
- Founded: 2019
- Employees: 90+
- Category: Biotech
Investment
Torl Biotherapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cormorant Asset Management: Verified investor in Series C
- BVF Partners: Verified investor in Series C
Key Investors
Cormorant Asset Management
Lead Investor
Verified investor in Series C
BVF Partners
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M